The UAE pain management drugs market is anticipated to expand at a high CAGR over the forecast period.
The United Arab Emirates (UAE) is poised to become a key competitor in the pain management medicines market, fueled by demographic changes, well-developed healthcare infrastructure, and rising prevalence of chronic diseases. Two main drivers spur the growth of the market: rising prevalence of chronic diseases and an aging population, in addition to favorable government support and investment in healthcare innovation. These elements have made the UAE a center of innovative pain management solutions in the Middle East, keeping pace with international trends for effective and safer pain relief measures.
The rising rate of chronic diseases, including arthritis, diabetes, and cancer, greatly fuels the requirements for pain relief medicines in the UAE. Chronic pain, which is usually linked to these ailments, impacts a large percentage of the population, which calls for drug interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and non-opioid painkillers.
With increasing economic and population growth in the UAE, cancer patient numbers will also increase substantially. The proportion of the population aged over 65, at cancer risk, will grow by 272% during 2022-2040. T he expectation of a growing cancer burden presents a challenge to patients, national health services, the economy, and society as a whole. Thus, this rise in cancer percentage drives the demand for cancer pain treatment solutions, such as opioid and non-opioid drugs, even further in the UAE.
The aging population in the UAE is yet another essential growth driver. With increased life expectancy comes the expansion of the geriatric population, which is more likely to suffer from chronic pain disorders such as osteoarthritis and neuropathic pain. The United Nations has estimated that the percentage of individuals aged 65 and above in the UAE will increase considerably by 2030, further increasing demand for pain relief medications. Such population dynamics combined with increased sensitivity towards the option of managing pain stimulate the use of new age therapies. Government programs and healthcare infrastructure development also play a crucial part.
On the other hand, the UAE Vision 2021 and subsequent health plans target world-class healthcare, which has led to investments in world-class facilities and regulatory systems that foster pharmaceutical research. The Dubai Health Authority's emphasis on curbing opioid abuse, for example, has encouraged interest in non-opioid alternatives in line with trends worldwide.
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Drug Type, Distribution Channel, Indication, Emirates |
| Geographical Segmentation | Abu Dhabi, Dubai, Sharjah, Ajman |
| Companies |
|